Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29482983

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Apr
First author
De Placido S

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Apr;19(4):431-432. doi: 10.1016/S1470-2045(18)30155-4.
    note
    Source null
    related pmid
    29482984
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016/S1470-2045(18)30213-4.
    note
    Source null
    related pmid
    29611521
    relationship
    Erratum in

Authors and identifiers

  1. name
    De Placido S
    type
    Author
  2. name
    Gallo C
    type
    Author
  3. name
    De Laurentiis M
    type
    Author
  4. name
    Bisagni G
    type
    Author
  5. name
    Arpino G
    type
    Author
  6. name
    Sarobba MG
    type
    Author
  7. name
    Riccardi F
    type
    Author
  8. name
    Russo A
    type
    Author
  9. name
    Del Mastro L
    type
    Author
  10. name
    Cogoni AA
    type
    Author
  11. name
    Cognetti F
    type
    Author
  12. name
    Gori S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    De Placido S
    type
    Author
  2. name
    Gallo C
    type
    Author
  3. name
    De Laurentiis M
    type
    Author
  4. name
    Bisagni G
    type
    Author
  5. name
    Arpino G
    type
    Author
  6. name
    Sarobba MG
    type
    Author
  7. name
    Riccardi F
    type
    Author
  8. name
    Russo A
    type
    Author
  9. name
    Del Mastro L
    type
    Author
  10. name
    Cogoni AA
    type
    Author
  11. name
    Cognetti F
    type
    Author
  12. name
    Gori S
    type
    Author
bibliography ids
  1. nci-bib-40da2eee8e0dc3f2de41e6ff
book metadata
content sha256
627636167d8a0cef94ca624e4955cee1461ac4d3aeae6770467b9e5ed8446b20
document type
citation
dois
  1. 10.1016/S1470-2045(18)30116-5
electronic publication date
display
2018 Feb 23
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29482983
immutable id
pubmed:29482983@627636167d8a0cef94ca624e4955cee1461ac4d3aeae6770467b9e5ed8446b20
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
474-485
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Apr;19(4):431-432. doi: 10.1016/S1470-2045(18)30155-4.
    note
    Source null
    related pmid
    29482984
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016/S1470-2045(18)30213-4.
    note
    Source null
    related pmid
    29611521
    relationship
    Erratum in
outcomes validated
false
pmid
29482983
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
1a68af11afabaa4133188dd8481fdb2ede5fcc2f7fc483214ebf9b42349f89de
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Apr
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29482983/
title
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

Preserved source evidence · Not medical advice